ATE236877T1 - N-(indolcarbonyl-)piperazinderivate als 5-ht2a- rezeptor liganden - Google Patents

N-(indolcarbonyl-)piperazinderivate als 5-ht2a- rezeptor liganden

Info

Publication number
ATE236877T1
ATE236877T1 AT00949288T AT00949288T ATE236877T1 AT E236877 T1 ATE236877 T1 AT E236877T1 AT 00949288 T AT00949288 T AT 00949288T AT 00949288 T AT00949288 T AT 00949288T AT E236877 T1 ATE236877 T1 AT E236877T1
Authority
AT
Austria
Prior art keywords
indolcarbonyl
receptor ligands
piperazine derivatives
ht2a receptor
ht2a
Prior art date
Application number
AT00949288T
Other languages
German (de)
English (en)
Inventor
Henning Boettcher
Hartmut Greiner
Juergen Harting
Gerd Bartoszyk
Christoph Seyfried
Amsterdam Christoph Van
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE236877T1 publication Critical patent/ATE236877T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AT00949288T 1999-07-22 2000-07-07 N-(indolcarbonyl-)piperazinderivate als 5-ht2a- rezeptor liganden ATE236877T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19934433A DE19934433A1 (de) 1999-07-22 1999-07-22 N-(Indolcarbonyl-)piperazinderivate
PCT/EP2000/006464 WO2001007435A2 (de) 1999-07-22 2000-07-07 N-(indolcarbonyl-)piperazinderivate als 5-ht2a-rezeptor liganden

Publications (1)

Publication Number Publication Date
ATE236877T1 true ATE236877T1 (de) 2003-04-15

Family

ID=7915702

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00949288T ATE236877T1 (de) 1999-07-22 2000-07-07 N-(indolcarbonyl-)piperazinderivate als 5-ht2a- rezeptor liganden

Country Status (26)

Country Link
US (2) US6838461B1 (https=)
EP (1) EP1198453B9 (https=)
JP (2) JP5242871B2 (https=)
KR (1) KR100779207B1 (https=)
CN (1) CN1229345C (https=)
AR (1) AR024819A1 (https=)
AT (1) ATE236877T1 (https=)
AU (1) AU770411B2 (https=)
BR (1) BR0012607A (https=)
CA (1) CA2383779C (https=)
CZ (1) CZ300510B6 (https=)
DE (2) DE19934433A1 (https=)
DK (1) DK1198453T5 (https=)
ES (1) ES2192535T3 (https=)
HK (1) HK1048636B (https=)
HU (1) HUP0201988A3 (https=)
MX (1) MXPA02000730A (https=)
MY (1) MY122531A (https=)
NO (1) NO322154B1 (https=)
PL (1) PL201893B1 (https=)
PT (1) PT1198453E (https=)
RU (1) RU2251548C2 (https=)
SK (1) SK286066B6 (https=)
UA (1) UA73518C2 (https=)
WO (1) WO2001007435A2 (https=)
ZA (1) ZA200201486B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589954B1 (en) 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
IL146309A (en) 1999-05-21 2008-03-20 Scios Inc Derivatives of the indole type and pharmaceutical preparations containing them as inhibitors of kinase p38
DE19934432A1 (de) * 1999-07-22 2001-02-01 Merck Patent Gmbh Indolderivate
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
US20020156453A1 (en) * 1999-10-14 2002-10-24 Pettis Ronald J. Method and device for reducing therapeutic dosage
US20020095134A1 (en) * 1999-10-14 2002-07-18 Pettis Ronald J. Method for altering drug pharmacokinetics based on medical delivery platform
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
DE10102053A1 (de) * 2001-01-17 2002-07-18 Merck Patent Gmbh Piperazinylcarbonylchinoline und -isochinoline
DE60212841T2 (de) 2001-06-15 2007-06-21 F. Hoffmann-La Roche Ag 4 piperazinylindolderivate mit affinität zum 5-ht6-rezeptor
WO2003002069A2 (en) * 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
DE10157673A1 (de) * 2001-11-24 2003-06-05 Merck Patent Gmbh Verwendung von N-(Indolcarbonyl-)piperazinderivaten
GB0203811D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
DE10212564B4 (de) * 2002-03-12 2007-04-19 Neurobiotec Gmbh 1-Allyl-ergotalkaloid-Derivate und ihre Verwendung zur Prophylaxe und Therapie von Migräne
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
AU2003262888A1 (en) * 2002-08-30 2004-03-19 Becton, Dickinson And Company Method of controlling pharmacokinetics of immunomodulatory compounds
DE10246357A1 (de) * 2002-10-04 2004-04-15 Merck Patent Gmbh Verwendung von 5-HT2Rezeptorantagonisten
AU2004264839B2 (en) * 2003-06-13 2009-06-04 Becton, Dickinson And Company Improved intra-dermal delivery of biologically active agents
AU2004270113A1 (en) * 2003-08-26 2005-03-17 Becton, Dickinson And Company Methods for intradermal delivery of therapeutics agents
WO2005091922A2 (en) * 2004-03-03 2005-10-06 Becton, Dickinson And Company Methods and devices for improving delivery of a substance to skin
CN101022806A (zh) * 2004-04-15 2007-08-22 萨马里坦药品公司 （4－烷基哌嗪基）（苯基）甲酮在治疗阿尔茨海默病中的应用
WO2005115360A2 (en) * 2004-05-11 2005-12-08 Becton, Dickinson And Company Formulations of anti-pain agents and methods of using the same
DE102004047517A1 (de) 2004-09-28 2006-03-30 Merck Patent Gmbh Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid
MX2007007558A (es) * 2004-12-21 2007-07-24 Hoffmann La Roche Derivados de tetralina y de indano y usos de los mismos.
GT200600042A (es) 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
AU2007248282B2 (en) * 2006-05-05 2011-12-08 Merck Patent Gmbh Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate
US7514433B2 (en) * 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
ES2379848T3 (es) * 2007-05-14 2012-05-04 Sk Biopharmaceuticals Co., Ltd. Compuesto arilpiperazina arilalcanoil carbomoiloxi novedoso, composiciones farmacéuticas que comprenden el compuesto y método para tratar el dolor, ansiedad y depresión al administrar el compuesto
EP2008656A1 (en) * 2007-06-28 2008-12-31 Bergen Teknologioverforing AS Compositions for the treatment of hyperphenylalaninemia
WO2009023253A2 (en) * 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
KR101062376B1 (ko) * 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
US9308323B2 (en) 2011-11-15 2016-04-12 Smiths Medical Asd, Inc. Systems and methods for illuminated medical tubing detection and management indicating a characteristic of at least one infusion pump
RU2549963C1 (ru) * 2014-04-08 2015-05-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дальневосточный государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО "ДВГМУ" Минздрава России) Способ прогнозирования развития критической печеночной недостаточности на основании сывороточного уровня селена
CA3014572C (en) 2016-02-25 2023-10-03 Asceneuron S.A. Acid addition salts of piperazine derivatives
GB2554371B (en) * 2016-09-22 2019-10-09 Resolute Energy Solutions Ltd Well apparatus and associated methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU630334B2 (en) 1987-09-24 1992-10-29 Jencap Research Ltd. Hormone preparations for hormone replacement therapy and contraceptive method
US5093341A (en) * 1987-12-17 1992-03-03 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine derivatives useful as antithrombolytic agents
US5032598A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
US5032604A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
US5330986A (en) * 1992-11-24 1994-07-19 Hoechst-Roussel Pharmaceuticals Inc. Indole-7-carboxamide derivatives
ZA954689B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
EP0922042A1 (en) 1996-08-09 1999-06-16 Smithkline Beecham Corporation Novel piperazine containing compounds
GB9718712D0 (en) * 1997-09-03 1997-11-12 Merck Sharp & Dohme Theraputic Agents
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
DE19934432A1 (de) * 1999-07-22 2001-02-01 Merck Patent Gmbh Indolderivate
JPWO2005099240A1 (ja) * 2004-04-07 2008-03-06 松下電器産業株式会社 情報交換支援装置、情報交換支援方法、及び情報交換支援プログラム

Also Published As

Publication number Publication date
CN1229345C (zh) 2005-11-30
CZ200268A3 (cs) 2002-04-17
BR0012607A (pt) 2002-04-09
CA2383779C (en) 2011-03-29
ZA200201486B (en) 2003-07-30
UA73518C2 (en) 2005-08-15
US20050096330A1 (en) 2005-05-05
DE19934433A1 (de) 2001-01-25
AR024819A1 (es) 2002-10-23
HK1048636B (zh) 2006-08-11
AU770411B2 (en) 2004-02-19
HUP0201988A2 (hu) 2002-11-28
JP5242871B2 (ja) 2013-07-24
DE50001729D1 (de) 2003-05-15
MY122531A (en) 2006-04-29
JP2012006940A (ja) 2012-01-12
PL201893B1 (pl) 2009-05-29
PT1198453E (pt) 2003-08-29
MXPA02000730A (es) 2002-08-20
EP1198453A2 (de) 2002-04-24
EP1198453B1 (de) 2003-04-09
EP1198453B9 (de) 2004-11-10
JP2003505458A (ja) 2003-02-12
KR20020019513A (ko) 2002-03-12
ES2192535T3 (es) 2003-10-16
PL353446A1 (en) 2003-11-17
CN1364157A (zh) 2002-08-14
SK512002A3 (en) 2002-05-09
CA2383779A1 (en) 2001-02-01
WO2001007435A3 (de) 2001-08-16
US7084143B2 (en) 2006-08-01
HK1048636A1 (en) 2003-04-11
KR100779207B1 (ko) 2007-11-27
AU6270400A (en) 2001-02-13
NO20020307L (no) 2002-03-21
NO20020307D0 (no) 2002-01-21
NO322154B1 (no) 2006-08-21
SK286066B6 (sk) 2008-02-05
WO2001007435A2 (de) 2001-02-01
DK1198453T3 (da) 2003-07-21
US6838461B1 (en) 2005-01-04
RU2251548C2 (ru) 2005-05-10
HUP0201988A3 (en) 2003-12-29
DK1198453T5 (da) 2005-01-31
CZ300510B6 (cs) 2009-06-03

Similar Documents

Publication Publication Date Title
DE50001729D1 (de) N-(indolcarbonyl-)piperazinderivate als 5-ht2a-rezeptor liganden
ATE299865T1 (de) Piperazinderivate verwendbar als ccr5 antagonisten
ATE253067T1 (de) Diazabicyloderivate als nikotin-acetylcholin- rezeptorliganden
ATE259363T1 (de) Piperazinderivate als 5-ht1b antagonisten
DE60032601D1 (de) Als antikrebsmittel verwendbare heterocyklische derivate
ATE299866T1 (de) Piperidinderivate verwendbar als ccr5 antagonisten
ATE258554T1 (de) Bicyclische imidazo-3-yl-aminderivate
ATE299142T1 (de) Phenylpiperazin-derivate als inhibitoren der serotonin-wiederaufnahme
ATE413403T1 (de) Bicyclische imidazo-5-yl-aminderivate
ATE270270T1 (de) Neuartige phenylalkyloxy-phenyl-derivate
EE200300189A (et) Sillatud piperasiinderivaadid
DE60003072D1 (de) Thiazolidindion-derivate als antidiabetika
IS6434A (is) Nýjar indól afleiður
DE50115858D1 (de) Heterocyclische aminoalkylpyridinderivate als psychopharmaka
ATE315025T1 (de) Ethansulfonyl-piperidin-derivate
DE60012953D1 (de) 3-amino-2-phenylpiperidinderivate als substanz p antagonisten
NO20022682L (no) Heterosykliske derivater
NO20021310D0 (no) Aminderivater
EE05580B1 (et) N-karbamolmetl-4-fenl-2-prrolidoon kasutamiseks isheemiavastase ravimina

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee